Each immune cell group has distinct metabolic requirements, activation pathways, and cytokine reliance. Standard, one-size-fits-all media cannot address these features. When studying diverse cell ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Ianalumab receives FDA Breakthrough Therapy status for Sjögren disease following positive findings from two phase 3 clinical trial programs.
Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI) have partnered on a new award, the ICRF-CRI ...
The FDA has granted breakthrough therapy designation to Novartis’ ianalumab for Sjögren’s disease, according to a press release from the manufacturer.In its statement, Novartis said it plans to submit ...
For a long time, neuroscientists treated this forgetting as a cognitive glitch or a simple lack of brainware maturity. But a ...
A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
US FDA grants Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease: Basel Monday, January 19, 2026, 12:00 Hrs [IST] Novartis announced that the US Fo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results